Progress of anti-angiogenesis targeted therapy of advanced osteosarcoma
10.3760/cma.j.issn.1006-9801.2019.07.017
- VernacularTitle:晚期骨肉瘤抗血管生成靶向治疗的研究进展
- Author:
Qiankun YANG
1
;
Yi PEI
;
Xiaojing ZHANG
Author Information
1. 中国医科大学肿瘤医院 辽宁省肿瘤医院骨与软组织科
- Keywords:
Osteosarcoma;
Angiogenic factors;
Molecular targeted therapy
- From:
Cancer Research and Clinic
2019;31(7):500-504
- CountryChina
- Language:Chinese
-
Abstract:
Osteosarcoma is a malignant tumor of mesenchymal origin and occurs mostly in young people, which is characterized with high malignancy, poor prognosis, easy recurrence and metastasis, as well as a great difficulty in treatment. Osteosarcoma is rich in blood supply, and its growth, invasion and metastasis highly depend on the tumor new angiogenesis. The process of angiogenesis is mainly initiated by various pro-angiogenic factors secreted by tumor cells, and the anti-angiogenic targeted therapy has been taken based on the targets spot and signal pathways of various angiogenic factors, which can effectively suppress the various biological behaviors of the osteosarcoma and improve the survival rate. However, a series of problems, such as drug resistance, side effects, different evaluation criteria, and difficulties in selecting effective treatment strategies also exist in the process of anti-angiogenesis therapy, and thus, further studies are needed. This paper mainly reviews the clinical trials of anti-angiogenic drugs, main barriers in usage, as well as the feasible treatment strategies in clinical practice.
